Production and nonclinical evaluation of an autologous iPSC–derived platelet product for the iPLAT1 clinical trial

Donor-derived platelets are used to treat or prevent hemorrhage in patients with thrombocytopenia. However, ∼5% or more of these patients are complicated with alloimmune platelet transfusion refractoriness (allo-PTR) due to alloantibodies against HLA-I or human platelet antigens (HPA). In these case...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugimoto, Naoshi, Nakamura, Sou, Shimizu, Shin, Shigemasa, Akiko, Kanda, Junya, Matsuyama, Nobuki, Tanaka, Mitsunobu, Hayashi, Tomoya, Fuchizaki, Akihiro, Nogawa, Masayuki, Watanabe, Naohide, Okamoto, Shinichiro, Handa, Makoto, Sawaguchi, Akira, Momose, Dai, Koh, Ki-Ryang, Tani, Yoshihiko, Takaori-Kondo, Akifumi, Eto, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706535/
https://www.ncbi.nlm.nih.gov/pubmed/36149941
http://dx.doi.org/10.1182/bloodadvances.2022008512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706535/
https://www.ncbi.nlm.nih.gov/pubmed/36149941
http://dx.doi.org/10.1182/bloodadvances.2022008512

Ejemplares similares